These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27154343)

  • 1. Asenapine-Induced Acute Dystonia in an Adolescent Male.
    Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asenapine: a clinical overview.
    Potkin SG
    J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine: a new antipsychotic option.
    Henry JM; Fuller MA
    J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
    Citrome L
    Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asenapine review, part II: clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
    Gerrits M; de Greef R; Peeters P
    Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Laryngeal Dystonia Associated With Asenapine Use: A Case Report.
    Collins N; Sager J
    J Clin Psychopharmacol; 2017 Dec; 37(6):738-739. PubMed ID: 29040152
    [No Abstract]   [Full Text] [Related]  

  • 10. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
    Frånberg O; Wiker C; Marcus MM; Konradsson A; Jardemark K; Schilström B; Shahid M; Wong EH; Svensson TH
    Psychopharmacology (Berl); 2008 Feb; 196(3):417-29. PubMed ID: 17940749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden-onset dystonia in a patient taking asenapine: interaction between ciprofloxacin and asenapine metabolism.
    Ridout KK; Ridout SJ; Pirnie LF; Puttichanda SP
    Am J Psychiatry; 2015 Nov; 172(11):1162-3. PubMed ID: 26575453
    [No Abstract]   [Full Text] [Related]  

  • 12. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.
    Fagiolini A; Forgione RN; Morana B; Maccari M; Goracci A; Bossini L; Pellegrini F; Cuomo A; Casamassima F
    Expert Opin Pharmacother; 2013 Mar; 14(4):489-504. PubMed ID: 23356509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
    Stepanova E; Grant B; Findling RL
    Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asenapine pharmacokinetics and tolerability in a pediatric population.
    Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AM; Findling RL; Jakate A; Carrothers TJ; Troyer MD
    Drug Des Devel Ther; 2018; 12():2677-2693. PubMed ID: 30214156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial.
    Sun X; Hamer R; McEvoy J
    J Clin Psychiatry; 2015 Jul; 76(7):992-3. PubMed ID: 26231009
    [No Abstract]   [Full Text] [Related]  

  • 17. Asenapine: a less effective, yet, more dangerous neuroleptic!
    Prescrire Int; 2012 Oct; 21(131):229-32. PubMed ID: 23185842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality rate is associated with aripiprazole once-monthly and oral asenapine administration.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2019 Jan; 39():22. PubMed ID: 30472350
    [No Abstract]   [Full Text] [Related]  

  • 19. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.
    Gerrits MG; de Greef R; Dogterom P; Peeters PA
    J Clin Pharmacol; 2012 May; 52(5):757-65. PubMed ID: 21628604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.